Assessment of Serum Levels of Advanced Oxidation Protein Products in Type 2 Diabetic Patients with and without Retinopathy Taking Different Antidiabetic Treatments

Authors

  • Sara Asaad Kadhim Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
  • Eman Saadi Saleh Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
  • Aymen Dheaa Jaafer Ministry of Health and Environment, Ibn AL-Haitham Hospital for Ophthalmology, Baghdad, Iraq

DOI:

https://doi.org/10.31351/vol32iss2pp74-82

Abstract

The goal of this study was to investigate the protein peroxidation role by measuring serum levels of advanced oxidation protein products (AOPP) in type 2 diabetic patients with or without retinopathy and comparing them to controls to see if circulating AOPP levels can be used as a detection biomarker for DR. And see which of the two widely used antidiabetic treatment groups had the most impact on this oxidative stress marker. The groups were divided into two subgroups: 1) 70 type 2 diabetic patients (36 male, 34 female), 35 with diabetic retinopathy (DR) and 35 with no evidence of DR, and 2) non-diabetic controls (11 male, 9 female) were chosen from Ibn AL-Haitham Hospital for Ophthalmology and a Specialized Center for Endocrinology and Diabetes. AOPP levels were significantly higher in diabetic patients with (12.5±5.6 ng/ml) or without DR (5.1±4 ng/ml) when compared to those of controls (1.45  0.8 ng/ml) (p<0.05). AOPP levels were higher in the late stage of DR compared to the early stage(14   3.15 ng/ml ) and ( 10  2.13 ng/ml) respectively so. Furthermore, Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) cause a better reduction in AOPP levels compared to Sulfonylureas (SUs) in the NDR group. Increased protein oxidation may involve in the pathogenesis and severity of DR and the serum AOPP levels have the prospect to become a marker for the diagnosis of DR. DPP-4 inhibitors were better in slowing the progression of the disease compared to SUs.

References

References

Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, et al. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. 2018;67(9):1867–79.

Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.

Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2(1):1–25.

Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428.

Rodríguez ML, Pérez S, Mena-Mollá S, Desco MC, Ortega ÁL. Oxidative stress and microvascular alterations in diabetic retinopathy: Future Therapies. Oxid Med Cell Longev. 2019.

Andersen N, Hjortdal JØ, Schielke KC, Bek T, Grauslund J, Laugesen CS, et al. The Danish registry of diabetic retinopathy. Clin Epidemiol. 2016;8:613.

Halliwell B. Free radicals and antioxidants–quo vadis? Trends Pharmacol Sci. 2011;32(3):125–30.

Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer. 2014;14(11):709–21.

Catala A. Lipid peroxidation of membrane phospholipids in the vertebrate retina. Front Biosci (Schol Ed). 2011;3:52–60.

Downloads

Published

2023-09-27

How to Cite

1.
Sara Asaad Kadhim, Eman Saadi Saleh, Aymen Dheaa Jaafer. Assessment of Serum Levels of Advanced Oxidation Protein Products in Type 2 Diabetic Patients with and without Retinopathy Taking Different Antidiabetic Treatments. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2023 Sep. 27 [cited 2024 Nov. 5];32(2):74-82. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2010